Compare GERN & OCSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GERN | OCSL |
|---|---|---|
| Founded | 1990 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 1996 | 2007 |
| Metric | GERN | OCSL |
|---|---|---|
| Price | $1.36 | $12.64 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 3 | 4 |
| Target Price | $2.17 | ★ $12.63 |
| AVG Volume (30 Days) | ★ 9.0M | 472.0K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 12.73% |
| EPS Growth | ★ 51.85 | N/A |
| EPS | N/A | ★ 0.20 |
| Revenue | ★ $1,065,000.00 | N/A |
| Revenue This Year | $26.91 | N/A |
| Revenue Next Year | $43.75 | $0.31 |
| P/E Ratio | ★ N/A | $63.30 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.04 | $10.63 |
| 52 Week High | $2.01 | $14.31 |
| Indicator | GERN | OCSL |
|---|---|---|
| Relative Strength Index (RSI) | 40.83 | 43.08 |
| Support Level | $1.24 | $12.31 |
| Resistance Level | $1.46 | $12.72 |
| Average True Range (ATR) | 0.08 | 0.21 |
| MACD | -0.02 | -0.09 |
| Stochastic Oscillator | 3.85 | 7.19 |
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
Oaktree Specialty Lending Corp is a specialty finance company. The company provides lending services and invests in small and mid-sized companies. The company's investment objective is to maximize its portfolio's total return by generating current income from debt investments, and to a lesser extent, capital appreciation from equity investments. The company provides customized, one-stop credit solutions to companies with limited access to public or syndicated capital markets. The company operates as a single reportable segment and derives revenues from investing in originated loans and other securities, including broadly syndicated loans, of U.S. private companies and manages the business on a consolidated basis.